

Shomron Ben Horin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303397/publications.pdf>

Version: 2024-02-01

237
papers

9,758
citations

41344

49
h-index

40979

93
g-index

243
all docs

243
docs citations

243
times ranked

7842
citing authors

#	ARTICLE	IF	CITATIONS
1	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 443-468.	1.3	804
2	Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. <i>Gastroenterology</i> , 2014, 147, 618-627.e3.	1.3	607
3	Review article: loss of response to anti-TNF treatments in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 987-995.	3.7	495
4	Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1444-1449.e1.	4.4	325
5	Optimizing anti-TNF treatments in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 24-30.	5.8	322
6	Optimizing Anti-TNF Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 550-557.e2.	4.4	312
7	Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 444-447.	4.4	291
8	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 522-530.e2.	4.4	268
9	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. <i>Gut</i> , 2014, 63, 1258-1264.	12.1	266
10	The immunogenic part of infliximab is the F(ab') ₂ , but measuring antibodies to the intact infliximab molecule is more clinically useful. <i>Gut</i> , 2011, 60, 41-48.	12.1	195
11	Infliximab-Related Infusion Reactions: Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 806-815.	1.3	178
12	Tailoring anti-TNF therapy in IBD: drug levels and disease activity. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 243-255.	17.8	165
13	Deep learning algorithms for automated detection of Crohn's disease ulcers by video capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 606-613.e2.	1.0	149
14	Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. <i>Gut</i> , 2016, 65, 1132-1138.	12.1	148
15	Deep learning for wireless capsule endoscopy: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 831-839.e8.	1.0	138
16	Systematic review with meta-analysis: loss of response and requirement of anti-TNF dose intensification in Crohn's disease. <i>Journal of Gastroenterology</i> , 2017, 52, 535-554.	5.1	133
17	Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 981-987.	4.4	128
18	Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. <i>American Journal of Gastroenterology</i> , 2015, 110, 1316-1323.	0.4	125

#	ARTICLE	IF	CITATIONS
19	Vedolizumab in IBD—Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 245-257.	1.3	119
20	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2026-2033.	1.9	118
21	Association of Vedolizumab Level, Anti-Drug Antibodies, and IgG2 Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 697-705.e7.	4.4	103
22	Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 555-558.	1.3	101
23	Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: Systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2017, 49, 854-863.	0.9	101
24	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 276-282.	3.7	98
25	Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 160, 2340-2353.	1.3	93
26	Large Symptomatic Pericardial Effusion as the Presentation of Unrecognized Cancer. <i>Medicine (United States)</i> , 2019, 98, 100.	1.0	90
27	Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1685-1696.	4.4	87
28	Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 171-182.	1.3	85
29	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 404-408.	1.9	84
30	Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1632-1641.	1.3	83
31	The Impact of Colon Cleanliness Assessment on Endoscopists' Recommendations for Follow-Up Colonoscopy. <i>American Journal of Gastroenterology</i> , 2007, 102, 2680-2685.	0.4	82
32	The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. <i>American Journal of Medicine</i> , 2005, 118, 636-640.	1.5	79
33	Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 194-198.	1.3	78
34	Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 356-364.	3.7	74
35	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1293-1299.	3.7	72
36	Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNF. <i>Gastroenterology</i> , 2022, 162, 454-467.	1.3	68

#	ARTICLE	IF	CITATIONS
37	The role of very late antigen-1 in immune-mediated inflammation. <i>Clinical Immunology</i> , 2004, 113, 119-129.	3.2	67
38	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 890-898.	0.4	67
39	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 525-531.	1.3	64
40	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 519-528.	8.1	63
41	Diagnostic Value of the Biochemical Composition of Pericardial Effusions in Patients Undergoing Pericardiocentesis. <i>American Journal of Cardiology</i> , 2007, 99, 1294-1297.	1.6	61
42	Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. <i>Digestive and Liver Disease</i> , 2019, 51, 1232-1240.	0.9	59
43	Prediction of patency capsule retention in known Crohn's disease patients by using magnetic resonance imaging. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 182-187.	1.0	57
44	Cholesterol Crystal Embolization To The Digestive System: Characterization of A Common, Yet Overlooked Presentation of Atheroembolism. <i>American Journal of Gastroenterology</i> , 2003, 98, 1471-1479.	0.4	56
45	Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. <i>Gut</i> , 2009, 58, 396-403.	12.1	56
46	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	1.9	56
47	Ulcer severity grading in video capsule images of patients with Crohn's disease: an ordinal neural network solution. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 187-192.	1.0	56
48	The outcome of a second preparation for colonoscopy after preparation failure in the first procedure. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 626-630.	1.0	54
49	The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 714-722.	3.7	53
50	Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2183-2190.	1.9	53
51	Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2327-2338.	1.9	50
52	Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares. <i>American Journal of Gastroenterology</i> , 2019, 114, 1142-1151.	0.4	50
53	Neuroimmunology of the gut: physiology, pathology, and pharmacology. <i>Current Opinion in Pharmacology</i> , 2008, 8, 490-495.	3.5	49
54	Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 490-499.	0.4	49

#	ARTICLE	IF	CITATIONS
55	Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 671-681.	3.0	48
56	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , 2022, 162, 482-494.	1.3	46
57	Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5+ B regulatory cells. <i>Stem Cell Research and Therapy</i> , 2016, 7, 109.	5.5	44
58	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 287-295.	8.1	44
59	Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1359-1372.e6.	4.4	43
60	Automated Detection of Crohn's Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 749-756.	1.3	43
61	The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 27-34.	3.0	42
62	Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 655-663.	3.2	41
63	Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878557.	3.2	41
64	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39
65	Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 2695.	3.3	39
66	The Lewis score or the capsule endoscopy Crohn's disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn's disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774778.	3.2	38
67	Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNF± Antagonists. <i>Frontiers in Immunology</i> , 2019, 10, 2921.	4.8	38
68	A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 544-551.	3.8	38
69	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 135-139.	0.9	37
70	Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2982-2990.	2.3	36
71	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1076-1085.	3.8	35
72	Familial clustering of Crohn's disease in Israel: Prevalence and association with disease severity. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 171-175.	1.9	33

#	ARTICLE	IF	CITATIONS
73	Therapeutic drug monitoring in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2014, 27, 304-312.	0.6	33
74	Optimizing biologic treatment in IBD: objective measures, but when, how and how often?. <i>BMC Gastroenterology</i> , 2015, 15, 178.	2.0	32
75	Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?. <i>Digestive Diseases</i> , 2014, 32, 384-388.	1.9	31
76	Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 266-276.	3.7	30
77	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	2.4	29
78	Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1627-1635.	1.9	28
79	Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 491-498.	1.5	26
80	Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1784-1794.	1.9	26
81	Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 120-123.	1.3	25
82	Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 507-512.	1.8	25
83	Magnetic resonance enterography or video capsule endoscopy – what do Crohn's disease patients prefer?. <i>Patient Preference and Adherence</i> , 2016, 10, 1043.	1.8	24
84	Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 69-75.	4.4	24
85	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	3.7	24
86	Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. <i>Gastroenterology</i> , 2019, 157, 1338-1351.e8.	1.3	24
87	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease"The Israeli real world experience. <i>Digestive and Liver Disease</i> , 2019, 51, 68-74.	0.9	24
88	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. <i>United European Gastroenterology Journal</i> , 2020, 8, 418-424.	3.8	24
89	Travel-Associated Health Risks for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 160-165.e1.	4.4	23
90	Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease. <i>Patient Preference and Adherence</i> , 2016, Volume 11, 23-31.	1.8	23

#	ARTICLE	IF	CITATIONS
91	Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 379-380.	1.3	22
92	Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a <i>post hoc</i> analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988159.	3.2	21
93	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 393-408.	1.9	21
94	Drug Levelâ€‘based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?. <i>Gastroenterology</i> , 2015, 148, 1268-1271.	1.3	20
95	Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy. <i>Clinical Radiology</i> , 2017, 72, 798.e7-798.e13.	1.1	20
96	Antigenic response to <sc>CT</sc>â€‘P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 507-522.	3.7	20
97	Significance of low level infliximab in the absence of anti-infliximab antibodies. <i>World Journal of Gastroenterology</i> , 2015, 21, 1907.	3.3	19
98	Impact of COVIDâ€‘19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 700-709.	2.8	17
99	Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877793.	3.2	16
100	Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2019, 19, 7.	2.0	16
101	Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1813-1821.	1.9	16
102	Dose optimisation for Loss of Response to Vedolizumabâ€‘ Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1707-1719.	1.3	16
103	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 781-794.	3.2	15
104	Intracavitary Contrast-enhanced Ultrasonography to Detect Enterovesical Fistula in Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, 315-317.	1.3	15
105	Structural bowel damage in quiescent Crohn's disease. <i>Digestive and Liver Disease</i> , 2017, 49, 490-494.	0.9	15
106	Reâ€‘phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2017, 5, 880-886.	3.8	15
107	Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohn's disease. <i>Abdominal Radiology</i> , 2018, 43, 3207-3212.	2.1	15
108	DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S066-S067.	1.3	15

#	ARTICLE	IF	CITATIONS
109	Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease. BMC Gastroenterology, 2017, 17, 27.	2.0	14
110	Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therapeutic Advances in Gastroenterology, 2017, 10, 397-406.	3.2	14
111	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterology Journal, 2021, 9, 91-101.	3.8	14
112	Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 313-320.	1.3	13
113	Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Alimentary Pharmacology and Therapeutics, 2018, 47, 1117-1125.	3.7	13
114	6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2621-2627.	1.9	13
115	Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. Clinical and Translational Gastroenterology, 2019, 10, e00015.	2.5	13
116	Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. Intestinal Research, 2020, 18, 200-209.	2.6	13
117	Rarity of adenomatous polyps in ulcerative colitis and its implications for colonic carcinogenesis. Endoscopy, 2016, 48, 215-222.	1.8	12
118	Monitoring of small bowel Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1047-1058.	3.0	12
119	Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 593-599.	1.3	12
120	Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. Inflammatory Bowel Diseases, 2020, 26, 1619-1625.	1.9	12
121	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476.	3.7	12
122	Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intestinal Research, 2016, 14, 322.	2.6	11
123	Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 11, j183.	1.3	11
124	The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn's disease in patients with negative ileocolonoscopy. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481876590.	3.2	11
125	Rising prevalence of celiac disease is not universal and repeated testing is needed for population screening. United European Gastroenterology Journal, 2019, 7, 412-418.	3.8	11
126	Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clinical Gastroenterology and Hepatology, 2021, 19, 1564-1572.e5.	4.4	11

#	ARTICLE	IF	CITATIONS
127	OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S021-S022.	1.3	11
128	Flare-up of ulcerative colitis after systemic corticosteroids: A strong case for Strongyloides. <i>World Journal of Gastroenterology</i> , 2008, 14, 4413.	3.3	10
129	Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 755-760.	2.3	10
130	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. <i>Digestive and Liver Disease</i> , 2019, 51, 1106-1111.	0.9	10
131	A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. <i>Frontiers in Medicine</i> , 2021, 8, 656493.	2.6	10
132	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
133	Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2868-2875.e1.	4.4	9
134	Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cells. <i>Journal of Clinical Immunology</i> , 2013, 33, 1395-1402.	3.8	8
135	Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. <i>World Journal of Gastroenterology</i> , 2017, 23, 2995.	3.3	8
136	Discontinuation of Biological Treatments in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 6-12.	2.2	8
137	Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 664-670.	2.8	8
138	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1330-1339.	1.9	8
139	The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211023.	3.2	8
140	Gastroenteritis-Associated Hyperamylasemia. <i>Archives of Internal Medicine</i> , 2002, 162, 689.	3.8	7
141	Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 382-389.	1.3	7
142	Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 453-463.	3.2	7
143	Assessment of patency capsule retention using MR diffusion-weighted imaging. <i>European Radiology</i> , 2017, 27, 4979-4985.	4.5	7
144	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1410-1417.	1.3	7

#	ARTICLE	IF	CITATIONS
145	CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 971-978.	3.1	7
146	Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 167-174.	3.8	7
147	Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00473.	2.5	7
148	Superficial abdominal thrombophlebitis (Mondor's disease) presenting as loss of response to adalimumab in a Crohn's disease patient. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1557-1558.	1.3	6
149	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 256-257.	1.3	6
150	P679 Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S458-S459.	1.3	6
151	Low 6-mercaptopurine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 679-685.	2.8	6
152	Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482091321.	3.2	6
153	Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. <i>Gut</i> , 2022, 71, 1988-1997.	12.1	6
154	Partners of patients with inflammatory bowel disease: how important is their support?. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 255.	2.3	5
155	Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease—Are We There Yet?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2753.	2.4	5
156	Change in bowel habits during menstruation: are IBD patients different?. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092980.	3.2	5
157	Infliximab levels and antibodies in IBD-related peripheral arthralgia. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1141-1148.	2.2	5
158	Detection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 742-745.	1.9	5
159	Evolution of Inflammatory Bowel Disease Research From a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 434-439.	1.9	5
160	Barriers to international travel in inflammatory bowel disease patients. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	5
161	Familial ulcerative colitis in Israeli Jews: its prevalence and clinical severity compared to sporadic disease. <i>Annals of Gastroenterology</i> , 2011, 24, 285-289.	0.6	5
162	Keeping it simple: mental health assessment in the Gastroenterology Department—using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110664.	3.2	5

#	ARTICLE	IF	CITATIONS
163	Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 760-762.	3.7	4
164	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e024222.	1.9	4
165	Evolution of colorectal cancer screening research in the past 25 years: text-mining analysis of publication trends and topics. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094115.	3.2	4
166	Risk of metachronous neoplasia on surveillance colonoscopy among young and older patients after polypectomy. <i>Digestive and Liver Disease</i> , 2020, 52, 427-433.	0.9	4
167	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 258-260.	8.1	4
168	P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S412-S414.	1.3	4
169	Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative Colitis. <i>Israel Medical Association Journal</i> , 2016, 18, 613-618.	0.1	4
170	A Giant Left Ventricular Pseudoaneurysm as a Late Sequela of Aortic Valve Endocarditis. <i>American Journal of the Medical Sciences</i> , 2003, 326, 375-377.	1.1	3
171	The Effect of Blockade of Tumor Necrosis Factor α on VLA-1+T-Cells in Rheumatoid Arthritis Patients. <i>Journal of Clinical Immunology</i> , 2007, 27, 580-588.	3.8	3
172	Biologics' switching: new insights toward establishing practice norms. <i>United European Gastroenterology Journal</i> , 2019, 7, 733-734.	3.8	3
173	P785 The prevalence of inflammatory bowel disease doubled in the last decade in Israel: an epidemiological national population-based study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S513-S514.	1.3	3
174	P571 Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S399-S400.	1.3	3
175	Localized pericardial inflammation in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 483-4.	0.8	3
176	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S029-S030.	1.3	2
177	Prediction of Recurrent Emergency Department Visits among Patients with Crohn's Disease: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3651.	2.4	2
178	Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. <i>Current Opinion in Pharmacology</i> , 2020, 55, 132-140.	3.5	2
179	Visible Worms in a Crohn's Patient Treated with Infliximab. <i>Gastroenterology</i> , 2021, 160, e10-e11.	1.3	2
180	Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 961-966.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Machine learning for prediction of intra-abdominal abscesses in patients with Crohn's disease visiting the emergency department. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110531.	3.2	2
182	P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNF \pm have significantly lower serologic responses. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i337-i338.	1.3	2
183	Acute Chest Pain as an Infusion Reaction to Vedolizumab. <i>Case Reports in Gastroenterology</i> , 2022, 16, 430-434.	0.6	2
184	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1509-1510.	4.4	1
185	Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 752-753.	1.3	1
186	Urine Dripping From the Sigmoid Wall in a Patient With Suspected Crohn's Disease: An Unusual Manifestation of a Colonovesical Fistula. <i>American Journal of Gastroenterology</i> , 2017, 112, 680.	0.4	1
187	Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 608-614.	2.8	1
188	Editorial: biomarker predictors of non-response to TNF \pm antagonists—the quest continues. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1089-1090.	3.7	1
189	Predictors of mortality in inflammatory bowel disease patients treated for pneumonia. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093945.	3.2	1
190	Body, Soul, and Hypnotherapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1083-1084.	1.3	1
191	Postoperative outcomes following inguinal hernia repair in inflammatory bowel disease patients compared to matched controls. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 522-526.	1.6	1
192	Reversal of Immunogenicity in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 125-127.	0.1	1
193	P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i382-i382.	1.3	1
194	Letter: loss of response to anti-TNF \pm agents in patients with inflammatory bowel disease depends on treatment duration. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 497-498.	3.7	1
195	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. <i>Vaccines</i> , 2022, 10, 376.	4.4	1
196	Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 1359.	2.4	1
197	Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD — authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 501-501.	3.7	0
198	PTU-072...Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016, 65, A88-A89.	12.1	0

#	ARTICLE	IF	CITATIONS
199	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 913-913.e2.	4.4	0
200	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 168.	4.4	0
201	P494 Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. Journal of Crohn's and Colitis, 2017, 11, S330-S330.	1.3	0
202	AODWE-008...Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn's disease with perianal fistula. , 2017, , .		0
203	PWE-033...Presentation and surgical interventions for crohn's disease with perianal fistula in the biologics era: results from a multicentre study. , 2017, , .		0
204	P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts. Journal of Crohn's and Colitis, 2017, 11, S183-S184.	1.3	0
205	P481 Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different therapeutic window between post-induction and maintenance treatment. Journal of Crohn's and Colitis, 2017, 11, S323-S324.	1.3	0
206	P779 CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls. Journal of Crohn's and Colitis, 2017, 11, S479-S479.	1.3	0
207	Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti-drug antibodies as useful guidance tools. Alimentary Pharmacology and Therapeutics, 2018, 47, 845-846.	3.7	0
208	P189 Diffusion-weighted magnetic resonance enterography for prediction of response to tumour necrosis factor inhibitors in stricturing Crohn's disease. Journal of Crohn's and Colitis, 2018, 12, S194-S194.	1.3	0
209	Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 575-576.	3.7	0
210	DOP36 Gut microbial variations in patients with quiescent Crohn's disease predict subsequent disease flare. Journal of Crohn's and Colitis, 2019, 13, S046-S047.	1.3	0
211	Letter: double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 822-823.	3.7	0
212	P332 Multinational comparisons of practices in overseas travel in Crohn's disease and ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S267-S267.	1.3	0
213	Assays used to assess biosimilarity of therapies for inflammatory bowel disease. Expert Opinion on Drug Discovery, 2020, 15, 139-144.	5.0	0
214	P221 Thromboembolic events in hospitalised patients with inflammatory bowel disease—a large tertiary hospital experience. Journal of Crohn's and Colitis, 2020, 14, S253-S253.	1.3	0
215	P643 Development of quantitative ultrasonographic activity score in ileal Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S532-S533.	1.3	0
216	P160 A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S218-S219.	1.3	0

#	ARTICLE	IF	CITATIONS
217	P402 Prediction of emergency department re-visit among Crohn's disease patients: a retrospective study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S372-S372.	1.3	0
218	P775 Evolution of inflammatory bowel disease research from a bird's eye perspective: A text-mining analysis of publication trends and topics. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S615-S615.	1.3	0
219	P718 Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S578-S579.	1.3	0
220	Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1198-1199.	3.7	0
221	Bottom-up: Can Trans-anal Rectal Resection Improve Outcomes in Ulcerative Colitis Patients Undergoing Proctocolectomy and Ileo-anal Pouch Anastomosis?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 724-725.	1.3	0
222	OUP accepted manuscript. <i>Journal of Crohn's and Colitis</i> , 2021, , .	1.3	0
223	Holistic approach to IBD patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1782-1782.	1.3	0
224	P014 Untargeted serum metabolome in longitudinal Crohn's Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S135-S135.	1.3	0
225	P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohn's disease visiting the emergency department. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S214-S214.	1.3	0
226	P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S307-S308.	1.3	0
227	Cytomegalovirus Limited to the Rectum in an Immunosuppressed IBD Patient. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e154-e155.	1.9	0
228	Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2021, , .	1.3	0
229	P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i254-i255.	1.3	0
230	P209 Disproportionate low albumin and high neutrophil-to-lymphocyte ratio in small bowel adenocarcinoma in long-term Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i267-i267.	1.3	0
231	P623 The effectiveness and tolerability of Crohn's disease exclusion diet in adult Crohn's disease patients: a retrospective study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i547-i548.	1.3	0
232	P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i451-i451.	1.3	0
233	Ultrasound-Tomographic Image Fusion: A Novel Imaging Technique for Follow-Up of Penetrating Complications of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, , .	1.9	0
234	A nerve-racking syncope. <i>Israel Medical Association Journal</i> , 2002, 4, 142-5.	0.1	0

#	ARTICLE	IF	CITATIONS
235	Hardly Anticipated capsule endoscopy finding. <i>Gastroenterology</i> , 2022, , .	1.3	0
236	Editorial: tofacitinib postmarketing safety reports among ulcerative colitis patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 131-132.	3.7	0
237	Risk factors and prediction algorithm for advanced neoplasia on screening colonoscopy for average-risk individuals. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211012.	3.2	0